Theratechnologies regains commercialization rights of EGRIFTA in Canada
It is indicated for the treatment of excess visceral adipose tissue, as evaluated by waist circumference = 95 cm for men and = 94 cm for women, and
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
Umeclidinium is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic. According to the company, Incruse contains 62.5mcg umeclidinium and is delivered